March 3, 2026Open Access

HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir

Key Points

HIV-1 persistence in deep tissues does not show resistance mutations to dolutegravir, indicating stable treatment response.
Transcriptional activity primarily arises from defective proviral DNA, contributing to ongoing HIV-1 detection.
Analysis of tissue samples indicates an absence of drug resistance mutations from intact HIV-1 proviruses while on therapy.
Identifying these mechanisms highlights the complexity of treatment, suggesting potential paths for future HIV-1 therapies.

Abstract

Despite ongoing transcriptional activity, persistence of HIV-1 in deep tissues is not associated with the selection of DRMs to dolutegravir on intact proviruses. Our results suggest that the detectable transcriptional activity stems predominantly from defective proviral DNA.

Bookmark

View Full Paper

Cite This Study

Mchantaf et al. (Tue,) studied this question.

synapsesocial.com/papers/69a75b2ac6e9836116a21fad https://doi.org/https://doi.org/10.1038/s43856-026-01405-z

Bookmark

View Full Paper